secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0000950170-23-061130
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana Biotechnology Q3 2023 GAAP net income $1.0M; cash $268.6M, pipeline data expected 2023-2024
--------------------------------------------------------------------------------

- Q3 2023 GAAP net income $1.0M driven by $82.6M gain from fair value changes on success payment liabilities.
- Cash position $268.6M; expects 2024 operating cash burn below $200M, runway into 2025.
- Phase 1 ARDENT trial for SC291 (CD19-directed CAR T) enrolling; initial data expected 2023, more robust in 2024.
- CTA submitted for IST of HIP-modified primary islet cells in type 1 diabetes; data expected 2023 and 2024.
- IND submitted for SC291 in B-cell autoimmune diseases; SC262 IND on track for 4Q 2023; data expected 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000095017023061130/0000950170-23-061130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000095017023061130/sana-20231108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-061130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer